Monte Rosa Therapeutics
GLUE15.3806.90% ( -1.140 )
Monte Rosa Therapeutics (GLUE)
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the bo...
- Open
- 16.640
- High
- 17.170
- Low
- 15.210
- Prev. Close
- 16.520
- Volume
- 2.32M
- Turnover
- 36.48M
- Avg Price
- 15.747
- Bid/Ask Ratio
- --
- Amplitude
- 11.86%
- 52wk High
- 25.770
- Volume Ratio
- 2.09
- Turnover Ratio
- 4.05%
Monte Rosa Therapeutics Analyst Rating
View MoreForecast & Rating
Jul 31, 2026Price forecast
$30.6799.39%
Forecast & RatingStrong buy
8analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 6 hours ago
Monte Rosa Therapeutics (NASDAQ:GLUE) Shares Down 4.1% After Analyst Downgrade
- Simplywall · 2 days ago, 02:13 AM
Why Monte Rosa Therapeutics (GLUE) Is Down 27.5% After Novo Nordisk’s ZEUS Trial Missed Its Goal
- Tip Ranks · Jul 31 at 01:45 PM
Buy Rating Maintained on Monte Rosa as Diversified Degrader Pipeline and Novartis Partnership Offset ZEUS Cardiovascular Setback
- businessinsider · Jul 31 at 01:16 PM
Monte Rosa, BioAge plunge as Novo’s setback casts a shadow over pipeline
- PUBT · Jul 17 at 03:05 PM
Monte Rosa CEO Markus Warmuth sells 9,500 shares worth $220,219.55
- PUBT · Jul 7 at 03:42 PM
Monte Rosa CSO Sharon Townson disposes of common shares worth $140,297.2
